| Dr Floyd Donald Colley, OD | |
|
2105 Town St, Pensacola, FL 32505-5117 | |
| (850) 433-0327 | |
| (850) 432-2159 |
| Full Name | Dr Floyd Donald Colley |
|---|---|
| Gender | Male |
| Speciality | Optometry |
| Experience | 58 Years |
| Location | 2105 Town St, Pensacola, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033211594 | NPI | - | NPPES |
| 084263000 | Medicaid | FL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 811 (Florida) | Primary |
| Provider Name | Dr F Donald Colley Optometrist P A |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1306004171 PECOS PAC ID: 0648328088 Enrollment ID: O20090423000334 |
News Archive
Waters Corporation (NYSE: WAT) today hosted Dr. Lawrence Zintek, National Organic Methods Development Expert, United States Environmental Protection Agency Region 5 Central Regional Laboratory in Chicago, and author of two new rapid screening methods for Alkylphenols and Bisphenol A (BPA) using Waters® ACQUITY UPLC®/Quattro Premier(TM) XE (UPLC/MS/MS) recently published in American Society for Testing and Materials (ASTM) International. Dr. Zintek was the keynote speaker at a Waters' breakfast seminar held in conjunction with the Water Quality Technology Conference sponsored by the American Water Works Association in Seattle.
Children born with cleft lip/palate go through extensive treatments that usually begin before their first birthday.
The Johns Hopkins Multiple Sclerosis Center is the recipient of one of 22 research grants offered to investigators in nine countries by the International Progressive MS Alliance, a worldwide collaborative focused on finding solutions to progressive forms of multiple sclerosis (MS).
Adding a direct acting anti-viral drug to the standard treatment regimen for hepatitis C significantly increases the cure rate in the most difficult to treat patients, according to a research report published Monday in the online edition of the journal The Lancet.The research team, led by Paul Kwo, M.D., of Indiana University School of Medicine, reported that adding the drug nearly doubled the treatment's effectiveness when given for 48 weeks in one treatment arm of the study.
Researchers at the University of Copenhagen have designed, produced and patented a new chemical compound for the possible treatment of brain damage caused by stroke. The compound binds 1,000 times more effectively to the target protein in the brain than the potential drug currently being tested on stroke victims.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Floyd Donald Colley, OD 2105 Town St, Pensacola, FL 32505-5117 Ph: (850) 433-0327 | Dr Floyd Donald Colley, OD 2105 Town St, Pensacola, FL 32505-5117 Ph: (850) 433-0327 |
News Archive
Waters Corporation (NYSE: WAT) today hosted Dr. Lawrence Zintek, National Organic Methods Development Expert, United States Environmental Protection Agency Region 5 Central Regional Laboratory in Chicago, and author of two new rapid screening methods for Alkylphenols and Bisphenol A (BPA) using Waters® ACQUITY UPLC®/Quattro Premier(TM) XE (UPLC/MS/MS) recently published in American Society for Testing and Materials (ASTM) International. Dr. Zintek was the keynote speaker at a Waters' breakfast seminar held in conjunction with the Water Quality Technology Conference sponsored by the American Water Works Association in Seattle.
Children born with cleft lip/palate go through extensive treatments that usually begin before their first birthday.
The Johns Hopkins Multiple Sclerosis Center is the recipient of one of 22 research grants offered to investigators in nine countries by the International Progressive MS Alliance, a worldwide collaborative focused on finding solutions to progressive forms of multiple sclerosis (MS).
Adding a direct acting anti-viral drug to the standard treatment regimen for hepatitis C significantly increases the cure rate in the most difficult to treat patients, according to a research report published Monday in the online edition of the journal The Lancet.The research team, led by Paul Kwo, M.D., of Indiana University School of Medicine, reported that adding the drug nearly doubled the treatment's effectiveness when given for 48 weeks in one treatment arm of the study.
Researchers at the University of Copenhagen have designed, produced and patented a new chemical compound for the possible treatment of brain damage caused by stroke. The compound binds 1,000 times more effectively to the target protein in the brain than the potential drug currently being tested on stroke victims.
› Verified 7 days ago
Gulf Coast Vision Center Optometrist Medicare: Medicare Enrolled Practice Location: 460 E Nine Mile Rd, Pensacola, FL 32514 Phone: 850-477-1499 Fax: 850-479-3359 | |
Jennifer M Werrell, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 8333 N. Davis Highway, West Flordia Medical Center Clinic Pa, Pensacola, FL 32514 Phone: 850-474-8220 Fax: 850-969-2187 | |
Dr. Matthew Steven Owens, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 460 E Nine Mile Rd, Pensacola, FL 32514 Phone: 850-477-1499 | |
Dr Francis X. Albert, Od, Pa Optometrist Medicare: Not Enrolled in Medicare Practice Location: 7171 N Davis Hwy, Sears Optical, Pensacola, FL 32504 Phone: 850-479-7517 | |
James William Andrews, Od Optometrist Medicare: Not Enrolled in Medicare Practice Location: 5062 Mobile Hwy, Pensacola, FL 32506 Phone: 850-453-4373 Fax: 850-453-1953 | |
Dr. Joseph Collin Tegenkamp, OD Optometrist Medicare: Medicare Enrolled Practice Location: 6700 N Davis Hwy, Pensacola, FL 32504 Phone: 850-434-6387 Fax: 850-432-0540 |